I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a Hong Kong...
Inspur Made an Appearance in the 2025 Hong Kong International InnoEX
BEIJING, April 16, 2025 /PRNewswire/ -- From April 13th to 16th, 2025, Inspur was invited to participate in the 2025 Hong Kong International Innovation and Technology Exhibition (InnoEX). This event focuses on innovative technology fields such as...